The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

naviscan.com

Founded Year

1995

Stage

Asset Sale | AssetsPurchased

Total Raised

$31.33M

About Naviscan

Naviscan has developed a breast cancer product which utilizes PET (Positron Emission Tomography) technologies.

Naviscan Headquarter Location

4401 Eastgate Mall

San Diego, California, 92121,

United States

858-587-3641

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Naviscan

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Naviscan is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Naviscan Patents

Naviscan has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/19/2006

12/20/2011

Medical equipment, Dosage forms, Medical imaging, Radioactivity, Drug delivery devices

Grant

Application Date

6/19/2006

Grant Date

12/20/2011

Title

Related Topics

Medical equipment, Dosage forms, Medical imaging, Radioactivity, Drug delivery devices

Status

Grant

Latest Naviscan News

CMR Naviscan Announces Molecular Breast Imaging Collaboration with Mayo Clinic

Nov 24, 2018

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact BioPortfolio . All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed by Alacrify Ltd .

  • When was Naviscan founded?

    Naviscan was founded in 1995.

  • Where is Naviscan's headquarters?

    Naviscan's headquarters is located at 4401 Eastgate Mall, San Diego.

  • What is Naviscan's latest funding round?

    Naviscan's latest funding round is Asset Sale.

  • How much did Naviscan raise?

    Naviscan raised a total of $31.33M.

  • Who are the investors of Naviscan?

    Investors of Naviscan include Compania Mexicana de Radiologia, Sanderling Ventures, Walker Ventures, QuestMark Partners, Active Angel Investors Network and 9 more.

  • Who are Naviscan's competitors?

    Competitors of Naviscan include Seno Medical Instruments, Micrima, Orison, Michelson Diagnostics, Gamma Medica and 11 more.

You May Also Like

M
Manoa Medical

Manoa Medical develops an advanced method of diagnosis and treatment of breast cancer.

K
Kjaya

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

H
Halo Healthcare

Halo Healthcare, formerly NeoMatrix, develops devices that allow women and doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test, is a fully automated, non-invasive breast cancer risk assessment device designed for use in the primary care setting as part of an annual well-woman visit. The HALO Breast Pap Test is FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.

S
Seno Medical Instruments

Seno Medical was formed to commercialize a new modality in cancer screening and diagnosis: laser opto-acoustic imaging. Unlike most screening techniques, which rely on anatomical imaging, Seno's goal is to bring functional imaging that can detect angiogenesis to the marketplace. Products for use with humans, focusing initially on breast cancer, are also in development for subsequent testing. Seno's patented technology integrates the use of lasers and acoustics to determine the presence of angiogenesis - the growth of blood vessels and higher blood volume that always surrounds a tumor. Per the company, unlike anatomical imaging techniques, such as mammography, laser opto-acoustic imaging can detect breast cancer, for example, at its earliest clinically stage (2 mm. versus 10 mm. with mammography) without patient discomfort or exposure to harmful x-ray.

M
Microwave Imaging System Technologies (MIST)

Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.

Micrima Logo
Micrima

Micrima is a Bristol-based company developing a safe, low-cost system to improve the detection of breast cancer. The imaging system captures high-resolution, 3D images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.